Radioembolization Therapy Market Trends and Forecast
The future of the global radioembolization therapy market looks promising with opportunities in the hospital, clinics, ambulatory surgical centers, and other markets. The global radioembolization therapy market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the rising cancer prevalence and increasing demand for targeted, minimally invasive therapies., the technological advancements enhancing precision and effectiveness of radioembolization treatments., and the rise in regulatory approvals and reimbursement policies.
• Lucintel forecasts that, within the type category, selective internal radiation therapy (SIRT) is expected to witness higher growth over the forecast period.
• Within the application category, hospital is expected to witness the higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Radioembolization Therapy Market
The radioembolization therapy market is evolving with several emerging trends, including the integration of advanced imaging techniques, combination therapies, and improved patient selection methods. As these trends gain traction, they are reshaping the way radioembolization is used in cancer care globally, driving its growth and application across diverse oncology fields.
• Advanced Imaging Techniques: The integration of cutting-edge imaging technologies such as PET/CT and MRI with radioembolization is enhancing the precision of treatment planning. These advanced imaging systems allow better localization of tumors, ensuring accurate delivery of Y-90 particles and reducing the risk of complications, which improves treatment outcomes.
• Combination with Other Therapies: Radioembolization is increasingly being combined with other treatment modalities like chemotherapy, immunotherapy, and targeted therapy to improve patient outcomes. By leveraging the synergistic effects of these therapies, clinicians can offer more comprehensive treatment options, particularly for patients with advanced liver cancer or metastatic tumors.
• Personalized Treatment Approaches: With advancements in genetic profiling and tumor biomarker identification, radioembolization is becoming more personalized. Tailoring treatments based on individual patient characteristics is expected to enhance efficacy and reduce side effects, leading to better long-term survival rates and a more refined approach to liver cancer treatment.
• Increased Clinical Research and Trials: The number of clinical trials investigating the efficacy of radioembolization for various cancers is growing. Ongoing studies aim to expand the indications of this therapy beyond hepatocellular carcinoma to include metastatic liver cancer, colorectal cancer, and other solid tumors, which could significantly broaden the market scope.
• Regulatory Approvals and Reimbursement Policies: As more regulatory bodies approve Y-90 radioembolization for liver cancer treatment, including reimbursement policies, the adoption rate of this therapy is expected to increase. More widespread insurance coverage, especially in countries like the U.S. and Germany, will enhance access to these life-saving treatments, driving market growth.
Emerging trends in the radioembolization therapy market, such as advanced imaging, combination therapies, and personalized medicine, are revolutionizing cancer care. These trends are increasing treatment efficacy and expanding the therapy’s applications, making radioembolization a critical tool in modern oncology. As these trends continue to develop, they will shape the future of cancer treatment, driving further market growth and accessibility.
Recent Development in the Radioembolization Therapy Market
Recent developments in the radioembolization therapy market are pushing the boundaries of cancer treatment and expanding its use in clinical settings worldwide. These developments are driven by technological advancements, regulatory approvals, and increasing global cancer rates, creating both challenges and opportunities for healthcare providers and manufacturers.
• FDA Approval of New Devices: Recent FDA approvals for next-generation Y-90 delivery systems are boosting the growth of the radioembolization market. These devices offer improved precision in delivering radioactive particles to tumors, enhancing the safety and effectiveness of treatment. This approval is encouraging broader adoption in the U.S. and other regulated markets.
• Increasing Adoption in Emerging Markets: The radioembolization therapy market is expanding in emerging economies such as India and China, where rising cancer incidence and improving healthcare infrastructure are driving demand. Partnerships between local healthcare providers and international device manufacturers are facilitating the wider adoption of Y-90 therapy in these regions.
• Integration with Personalized Medicine: There has been a growing trend to combine radioembolization with personalized medicine approaches. The ability to tailor treatments based on genetic markers and tumor biology is improving outcomes and minimizing side effects. This trend is particularly important in precision oncology and is expected to become more widespread.
• Research Advancements in Combination Therapies: Studies exploring the combination of radioembolization with chemotherapy, immunotherapy, and targeted therapies are showing promising results, particularly in liver cancer. These research advancements are driving innovation and offering new treatment options for patients who previously had limited alternatives.
• Improved Reimbursement Policies: Many countries are updating reimbursement policies to include radioembolization therapy for liver cancer, expanding patient access to this treatment. In the U.S. and Europe, insurance coverage for Y-90 radioembolization is increasingly becoming more inclusive, facilitating broader adoption by healthcare providers.
Recent developments in the radioembolization therapy market, such as device innovations, clinical research, and regulatory advancements, are significantly driving its global adoption. These developments are enhancing the effectiveness of treatments, expanding market reach, and ensuring that more patients have access to this life-saving therapy, ultimately reshaping the landscape of cancer care.
Strategic Growth Opportunities in the Radioembolization Therapy Market
The radioembolization therapy market offers significant growth opportunities across multiple applications, including liver cancer, metastatic cancers, and combination therapies. The increasing demand for minimally invasive cancer treatments, especially in emerging markets, presents substantial opportunities for companies to expand their product offerings and capture a larger market share.
• Liver Cancer Treatment: As the most common application for radioembolization, liver cancer offers substantial growth opportunities. Increasing liver cancer incidence worldwide, particularly in Asia and the U.S., is fueling demand for Y-90 radioembolization. Expanding clinical use and improving accessibility will drive market growth in this area.
• Metastatic Liver Cancer: Expanding the use of radioembolization in metastatic liver cancer is a significant growth opportunity. Research and clinical trials are investigating its effectiveness in treating tumors that have spread from other organs, such as colorectal cancer, which could open up new markets for radioembolization therapy.
• Combination with Immunotherapy: Combining radioembolization with immunotherapy represents a promising growth opportunity. Clinical trials exploring the synergistic effects of these treatments for liver cancer and other tumors are likely to lead to more comprehensive treatment regimens, boosting demand for radioembolization therapy.
• Expansion in Emerging Markets: Emerging markets such as India, China, and Latin America are seeing an increase in cancer diagnoses and healthcare investments, creating significant growth opportunities. Local healthcare infrastructure improvements and partnerships with global manufacturers are expected to drive the adoption of radioembolization therapy in these regions.
• Regulatory Approvals and Market Access: Securing regulatory approvals in additional countries, particularly in regions like the Middle East and Africa, offers significant growth potential. Market expansion can be facilitated through collaborations with local distributors and healthcare providers to improve accessibility and patient access to treatment.
Strategic growth opportunities in the radioembolization therapy market are emerging across several key applications, including liver cancer, metastatic liver cancer, and combination therapies. Expanding access in emerging markets and securing regulatory approvals will play a crucial role in accelerating market growth. These opportunities are expected to drive increased adoption and the evolution of the radioembolization landscape.
Radioembolization Therapy Market Driver and Challenges
The radioembolization therapy market is influenced by a combination of drivers and challenges. Key drivers include technological advancements, rising cancer incidences, and favorable regulatory changes. However, the market faces challenges such as high treatment costs, limited accessibility in low-income regions, and reimbursement issues, which could impact its expansion in certain areas.
The factors responsible for driving the Global Radioembolization Therapy market include:
1. Technological Advancements: The continuous development of Y-90 delivery systems, along with better imaging technologies, is enhancing the precision and effectiveness of radioembolization therapy. These advancements allow more accurate tumor targeting and minimal damage to surrounding healthy tissue, improving patient outcomes.
2. Rising Cancer Incidence: The increasing prevalence of liver cancer, especially hepatocellular carcinoma (HCC), and metastatic liver cancer globally is driving the demand for innovative treatments like radioembolization. As cancer rates rise, the need for effective therapies like Y-90 is growing rapidly.
3. Government Support and Funding: Increased government funding for healthcare infrastructure and cancer research, particularly in emerging markets, is accelerating the adoption of radioembolization. Government initiatives, along with supportive reimbursement policies, make these therapies more accessible to patients and healthcare providers.
4. Minimally Invasive Treatment Demand: There is growing demand for minimally invasive treatments that offer lower risks and faster recovery times. Radioembolization is gaining popularity due to its ability to target tumors precisely without requiring extensive surgery, appealing to both patients and healthcare providers.
5. Expansion of Clinical Research: Ongoing clinical trials are expanding the indications for radioembolization beyond liver cancer. Research into its application in other cancers, such as colorectal and gastrointestinal cancers, is likely to open up new markets and treatment avenues, driving growth.
Challenges in the Global Radioembolization Therapy market are:
1. High Costs: The high cost of radioembolization therapy, including the cost of Y-90 particles, equipment, and associated treatments, can be a significant barrier for adoption, particularly in low-income regions or countries with less developed healthcare systems.
2. Limited Access in Low-Income Regions: Despite growing demand, radioembolization therapy remains relatively inaccessible in many low-income regions due to the high costs of treatment, limited healthcare infrastructure, and lack of trained professionals.
3. Reimbursement Issues: In some regions, insurance coverage for radioembolization therapy is limited or non-existent, which can hinder patient access. The lack of universal reimbursement policies and inconsistent coverage across regions remains a major challenge to market growth.
The radioembolization therapy market is driven by technological innovations, rising cancer incidence, and government support, but faces challenges such as high treatment costs and limited access in some regions. Addressing these challenges while leveraging growth drivers will be crucial for expanding market adoption and ensuring more patients can benefit from this life-saving therapy.
List of Radioembolization Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioembolization therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioembolization therapy companies profiled in this report include-
• Terumo Corporation
• Merit Medical Systems Inc.
• Cook Medical
• Boston Scientific Corporation
• Medtronic Plc
Radioembolization Therapy Market by Segment
The study includes a forecast for the global radioembolization therapy market by type, application, and region.
Radioembolization Therapy Market by Type [Value from 2019 to 2031]:
• Transarterial Radioembolization (TARE)
• Selective Internal Radiation Therapy (SIRT)
Radioembolization Therapy Market by Application [Value from 2019 to 2031]:
• Hospital
• Clinics
• Ambulatory Surgical Centers
• Other
Radioembolization Therapy Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Radioembolization Therapy Market
The radioembolization therapy market has seen substantial growth in recent years, driven by technological advancements and increasing adoption in the treatment of liver cancer, especially in the United States, China, Germany, India, and Japan. As a minimally invasive treatment option, radioembolization is gaining recognition for its effectiveness in targeting tumors while minimizing damage to surrounding healthy tissue. This trend is shaping the future of cancer therapy in key global markets.
• United States: The United States has emerged as a leader in the radioembolization therapy market due to its advanced healthcare infrastructure and growing demand for innovative cancer treatments. The adoption of Yttrium-90 (Y-90) radioembolization therapy for hepatocellular carcinoma (HCC) and metastatic liver cancer is increasing. Regulatory bodies like the FDA have approved new devices and therapies, encouraging broader use. Furthermore, ongoing clinical trials and insurance coverage for radioembolization are further expanding its accessibility and application in oncology.
• China: China’s radioembolization therapy market is growing rapidly, fueled by rising cancer incidence, particularly liver cancer, which is the most common cancer in the country. The Chinese government has been heavily investing in expanding healthcare services, which includes the development of interventional oncology treatments like radioembolization. Additionally, partnerships between Chinese hospitals and international medical device companies are increasing, facilitating the adoption of Y-90 radioembolization therapy in both urban and rural settings, improving access to life-saving treatments.
• Germany: Germany has maintained its strong presence in the radioembolization therapy market, driven by advanced medical technologies and well-established healthcare systems. The country is seeing growing use of radioembolization in treating liver cancer, as hospitals increasingly integrate it into clinical practice. There is also an emphasis on combining radioembolization with other therapeutic modalities, such as chemotherapy and immunotherapy, to enhance treatment outcomes. Research institutions in Germany are pushing the boundaries of personalized medicine in this field.
• India: In India, the radioembolization therapy market is still in its early stages, but it is witnessing rapid growth, particularly in metro cities with advanced healthcare infrastructure. The increasing burden of liver diseases, including HCC, is driving demand for innovative therapies. With rising awareness and improved access to healthcare facilities, more hospitals are incorporating radioembolization into their cancer treatment regimens. However, cost remains a barrier, and initiatives aimed at reducing the financial burden are crucial for broader adoption.
• Japan: Japan is embracing radioembolization therapy, particularly for liver cancer, thanks to its robust healthcare system and aging population. Japanese physicians are increasingly adopting Y-90 radioembolization, particularly in combination with other treatment approaches such as surgical resection and liver transplantation. The country is also advancing research on the use of radioembolization for various cancers beyond hepatocellular carcinoma, with growing clinical interest in its application for metastatic liver cancer and gastrointestinal tumors.
Features of the Global Radioembolization Therapy Market
Market Size Estimates: Radioembolization therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Radioembolization therapy market size by type, application, and region in terms of value ($B).
Regional Analysis: Radioembolization therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the radioembolization therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioembolization therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for radioembolization therapy market?
Answer: The global radioembolization therapy market is expected to grow with a CAGR of 3.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the radioembolization therapy market?
Answer: The major drivers for this market are the rising cancer prevalence and increasing demand for targeted, minimally invasive therapies., the technological advancements enhancing precision and effectiveness of radioembolization treatments., and the rise in regulatory approvals and reimbursement policies.
Q3. What are the major segments for radioembolization therapy market?
Answer: The future of the radioembolization therapy market looks promising with opportunities in the hospital, clinics, ambulatory surgical centers, and other markets.
Q4. Who are the key radioembolization therapy market companies?
Answer: Some of the key radioembolization therapy companies are as follows:
• Terumo Corporation
• Merit Medical Systems Inc.
• Cook Medical
• Boston Scientific Corporation
• Medtronic Plc
Q5. Which radioembolization therapy market segment will be the largest in future?
Answer: Lucintel forecasts that selective internal radiation therapy (SIRT) is expected to witness higher growth over the forecast period.
Q6. In radioembolization therapy market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the radioembolization therapy market by type (transarterial radioembolization (TARE) and selective internal radiation therapy (SIRT)), application (hospital, clinics, ambulatory surgical centers, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Radioembolization Therapy Market, Radioembolization Therapy Market Size, Radioembolization Therapy Market Growth, Radioembolization Therapy Market Analysis, Radioembolization Therapy Market Report, Radioembolization Therapy Market Share, Radioembolization Therapy Market Trends, Radioembolization Therapy Market Forecast, Radioembolization Therapy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.